By Dominic Chopping
STOCKHOLM--Swedish buyout group EQT and French pharmaceutical major Sanofi co-led a $135 million series B financing round in Spanish biotech company SpliceBio.
EQT co-led the funding round with Sanofi Ventures, while Roche Venture Fund and all existing investors also participated.
SpliceBio is developing therapies for genetic diseases using protein splicing technology.
Proceeds from the funding will support the company's phase 1/2 clinical development of SB-007, a therapy being developed to treat Stargardt disease, a genetic eye disorder that causes progressive vision loss and blindness.
Funding will also advance a broader pipeline of genetic medicines targeting indications in ophthalmology, neurology, and other therapeutic areas.
Daniela Begolo, Managing Director at EQT Life Sciences, will join the SpliceBio board of directors.
Existing investors in SpliceBio include New Enterprise Associates, UCB Ventures, Ysios Capital, Gilde Healthcare, Novartis Venture Fund, and Asabys Partners.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
June 11, 2025 04:10 ET (08:10 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。